Willow Shah-Neville, Author at Labiotech.eu

About

Graduated with a degree in BA Journalism from the University of South Wales (Cardiff) in 2021. Shortly afterwards, I fell into content writing for a couple of different companies writing about different subjects including science, tech, crypto, lifestyle etc. But journalism is where my heart truly lies, and just before I landed my role here, I did a journalism internship with an online publication called TheSocialTalks, where I finally had an opportunity to get my journalistic work published. The rest is history and, having always been interested in biology and medical science, I’m now living my dream as a junior reporter here at Labiotech. Outside of work, hobbies include reading, TV & Film, cooking, travelling, eating out, and a decent amount of wine tasting…

Articles by Willow Shah-Neville

In Depth 7 Dec 2023

The biggest private biotech investments in November 2023

The companies Cambrian Innovation, Terremoto Biosciences, and VectorY Therapeutics bagged the biggest biotech investments in November 2023. Around the world, oncology and central nervous system players attracted the biggest funding rounds. As we edge closer to Christmas, biotech fundraising appears to be drying up a bit; there was a significant decrease in funding rounds in […]

December 7, 2023 - 3 minutesmins - By Willow Shah-Neville

News and Trends 6 Dec 2023

A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy

Still a relatively new technology, CRISPR has been heralded in recent years as having the potential to tackle a range of diseases. And now, it has finally proved its worth. In a world first, the U.S. Food and Drug Administration (FDA) has approved CASGEVY – the CRISPR-based gene therapy developed by Vertex Pharmaceuticals and CRISPR […]

December 6, 2023 - 6 minutesmins - By Willow Shah-Neville

Best in Biotech 28 Nov 2023

Five companies shaping Texas’ growing biotech hubs

Thanks to the U.S. government’s ambitious plans to advance American biotech and biomanufacturing, Texas’ life sciences hubs, particularly in Dallas and Houston, are now one of many in the country that are currently thriving. In this article, we take a closer look at several biotech companies in Texas taking advantage of the additional investment in […]

November 28, 2023 - 8 minutesmins - By Willow Shah-Neville

Geographic atrophy treatment: Apellis' Syfovre vs. Astellas' Izervay.

In Depth 22 Nov 2023

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […]

November 22, 2023 - 8 minutesmins - By Willow Shah-Neville

Best in Biotech 21 Nov 2023

Beyond insulin: six cutting-edge diabetes biotech companies you should know about

As we predicted last year, the diabetes market is booming, particularly after the incredible success of new diabetes drugs like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro. There are now several diabetes biotech companies that are garnering attention, all with their own innovative solutions to tackling both type 1 and type 2 diabetes. The prevalence […]

November 21, 2023 - 7 minutesmins - By Willow Shah-Neville

In Depth 16 Nov 2023

Meet the ‘biotech mafia’: how specialized biotech VC firms are dominating industry funding once again

Between 2020 and 2022 – largely due to the biotech innovations that came about by the COVID-19 pandemic – there was an influx of generalist investors in the biotech industry, betting big on new technologies like mRNA vaccines. But, now, these investors appear to have backed off, leaving room for specialized biotech venture capital (VC) […]

November 16, 2023 - 6 minutesmins - By Willow Shah-Neville

Best in Biotech 14 Nov 2023

10 biotech companies leading innovation in the Asia-Pacific region

Asia-Pacific is now establishing itself as a global innovation hub, with China, Japan, and Korea leading the space in overall innovative pipeline assets in the region. The life sciences industry is thriving, and there has been a shift in the region from predominantly producing generics to developing innovative technologies, with several Asia-Pacific biotech companies leading […]

November 14, 2023 - 11 minutesmins - By Willow Shah-Neville

Weekly Roundup 10 Nov 2023

Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs

You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under the name Korro Bio, Inc. […]

November 10, 2023 - 12 minutesmins - By Willow Shah-Neville

In Depth 6 Nov 2023

The biggest private biotech investments in October 2023

The companies Aiolos Bio, MapLight Therapeutics and Agomab Therapeutics bagged the biggest biotech investments in October 2023. Around the world, biomaterials, central nervous system and musculoskeletal disorder players attracted the most investor interest. October 2023 saw a lot of fundraising taking place both in and out of healthcare in the U.S. and Europe. However, the […]

November 6, 2023 - 3 minutesmins - By Willow Shah-Neville

In Depth 2 Nov 2023

How French pharma giant Sanofi is betting big on AI

The benefits of artificial intelligence (AI) in shaping clinical research and trials have given rise to many new AI-driven biotech startups. According to a recent report, the number of AI companies involved in drug discovery and development increased from 62 in 2011 to 400 in 2022. This AI-driven transformation is catching the attention of big pharma […]

November 2, 2023 - 8 minutesmins - By Willow Shah-Neville

In Depth 30 Oct 2023

The ongoing search for an HIV cure: can CRISPR crack the code?

HIV continues to represent a global health burden, with the World Health Organization (WHO) estimating that, in 2022, there were 39 million people living with the virus. But there is still no effective cure for it. The only option patients have is antiretroviral therapy, which, although it represents a major milestone in HIV treatment and […]

October 30, 2023 - 7 minutesmins - By Willow Shah-Neville

In Depth 26 Oct 2023

Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials

Alzheimer’s disease is the most common form of dementia – which currently affects more than 55 million people globally – making up 60% to 70% of cases. It is a complex disease, encompassing multiple interrelated and progressive destructive processes in the brain, resulting in neuron damage that extends to parts of the brain that enable […]

October 26, 2023 - 11 minutesmins - By Willow Shah-Neville

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Willow Shah-Neville

About

Articles by Willow Shah-Neville

The biggest private biotech investments in November 2023

A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy

Five companies shaping Texas’ growing biotech hubs

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Beyond insulin: six cutting-edge diabetes biotech companies you should know about

Meet the ‘biotech mafia’: how specialized biotech VC firms are dominating industry funding once again

10 biotech companies leading innovation in the Asia-Pacific region

Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs

The biggest private biotech investments in October 2023

How French pharma giant Sanofi is betting big on AI

The ongoing search for an HIV cure: can CRISPR crack the code?

Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Willow Shah-Neville

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!